Schonfeld Strategic Advisors LLC Zentalis Pharmaceuticals, Inc. Transaction History

Schonfeld Strategic Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$19.63 - $28.29 $292,487 - $421,521	14,900 New	14,900 $298,000
Q1 2022 May 16, 2022	SELL	$41.58 - $80.89 $357,588 - $695,654	-8,600 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$66.92 - $84.79 $1.38 Million - $1.75 Million	-20,687 Reduced 70.64%	8,600 $723,000
Q3 2021 Nov 16, 2021	BUY	$46.83 - $73.5 $395,760 - $621,148	8,451 Added 40.56%	29,287 $1.95 Million
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $779,474 - $1.3 Million	20,836 New	20,836 $1.11 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.